Navigation Links
InspireMD Reports 2012 Fiscal Year Results
Date:9/12/2012

TEL AVIV, Israel, September 12, 2012 /PRNewswire/ --

InspireMD, Inc. (OTC BB NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary embolic protection stent platform technology for use in patients with Acute Myocardial Infarctions, today announced financial results for the six months ended June 30, 2012.

As previously announced, the Company changed its fiscal year end to June 30. As a result, the six months ended June 30, 2012 represent a transition period, with the next fiscal year covering the period from July 1, 2012 through June 30, 2013

"Several key milestones were achieved during the six months ended June 30, 2012," said Ofir Paz, Co-founder and CEO of InspireMD.  We completed enrollment in the nine-country, 433-patient MASTER trial ahead of schedule, raised $11 million with a convertible debt offering and strengthened senior management.

"Subsequently, on August 20, we received notice that the MASTER trial comparing the MGuard™ embolic prevention stent to commercially-approved bare metal or drug-eluting stents in heart attack patients undergoing primary percutaneous coronary intervention (PCI) demonstrated a positive outcome," he added. "This is a significant milestone for InspireMD.  We are eagerly awaiting presentation of the study's findings at the Transcatheter Cardiovascular Therapeutics (TCT) meeting next month in Miami."

The MASTER (MGuard for Acute ST Elevation Reperfusion) trial is the first company-sponsored randomized clinical study of the MGuard™ embolic protection stent.

In eleven prior single arm studies and a 40-patient physician-sponsored randomized trial, the MGuard™ embolic protection stent showed effectiveness in restoring blood flow and reducing major adverse events following heart attack stenting.

About 3.2 m
'/>"/>

SOURCE InspireMD, Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
2. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
3. InspireMD Appoints Dr. James Barry to Its Board of Directors
4. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
5. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
6. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018: China Market Research Reports
7. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
8. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2013
9. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
10. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
11. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Ondine Biopharma,Corporation (TSX: OBP; AIM: OBP), a ... that a poster entitled,"Photodisinfection in the Treatment ... representatives at the American Academy of,Periodontology,s (AAP) ... being,held at the Washington State Convention and ...
... XI,AN, China, Sept. 5 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical ... leading developer and producer of plant extracts and ... food production in,Xi,an, China, is pleased to announce ... arrangement with Xi,an Qinba Xintong Medical Ltd. ("Qinba").,Under ...
... MEDQ ) today announced that its board of directors has ... join the board, effective,September 4, 2008. Prior to the election ... of the board from seven to 10 members., According ... to have this opportunity to further enhance the quality and,experience ...
Cached Biology Technology:Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontology's 94th Annual Meeting 2Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd. 2MedQuist Announces Additions to Board of Directors 2MedQuist Announces Additions to Board of Directors 3
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... very good at what they do. But they don,t ... work in oily or dangerous environments, or in any kind ... of the fastest and most maneuverable creatures on the planet, ... to their streamlined bodies and a finely tuned muscular/sensory/control system. ...
... Rochelle, NY, September 19, 2012 Many biotech observers ... be based on the field of personalized medicine, ... ( GEN ) ( http://genengnews.com ). Although drug ... of biosamples, demand is exceeding supply, fueling the ...
... researchers at Michigan State University has documented the step-by-step process ... in the current issue of Nature , are revealed ... coli bacteria figured out how to supplement a traditional ... "It,s pretty nifty to see a new biological function evolve," ...
Cached Biology News:Robotic tuna is built by Homeland Security 2Evolution is as complicated as 1-2-3 2